Measles Virus Vector Reprogramming With miR375 for Safer iPSCs

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for generating induced pluripotent stem cells (iPSCs) face inefficiencies, safety concerns, and risks of tumorigenicity due to sustained expression of reprogramming factors and vector-integration-mediated insertional mutagenesis.

Innovation Solution

Utilization of a measles virus (MV) vector containing multiple reprogramming factors (OCT4, SOX2, KLF4, and cMYC) with a microRNA (miR375) to enhance reprogramming efficiency and safety, minimizing tumorigenicity and vector integration risks.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If reprogramming factors are sustainedly expressed to ensure complete reprogramming, then reprogramming efficiency is improved, but tumorigenicity risk increases

Engineering Contradiction:

Improvereprogramming efficiencyVSAvoidtumorigenicity risk

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent uses inducible promoter systems (such as doxycycline-inducible promoters) to control the temporal expression of reprogramming factors. The factors are expressed at high levels during the reprogramming phase, then expression is turned off or reduced after pluripotency is achieved, thereby maintaining high reprogramming efficiency while minimizing prolonged exposure that could cause tumorigenesis

Inventive Principle:

Principle #19Periodic action

Solution Approach 2:

The patent employs conditional expression systems that allow dynamic adjustment of reprogramming factor expression levels. By changing external parameters (such as adding/removing inducers like doxycycline or changing small molecule concentrations), the expression level of reprogramming factors can be optimized for each stage of reprogramming, achieving complete reprogramming while reducing tumorigenicity risk through parameter control

Inventive Principle:

Principle #35Parameter changes

2Productivity

If viral vectors are used to deliver reprogramming factors, then delivery efficiency is improved, but insertional mutagenesis risk increases

Engineering Contradiction:

Improvedelivery efficiencyVSAvoidinsertional mutagenesis risk

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent divides the delivery system into multiple components: viral vectors deliver only the reprogramming factor genes without integrating into the host genome, while separate non-integrating elements (such as episomal plasmids or mRNA) provide additional factors. This segmentation maintains high delivery efficiency through viral transduction while eliminating insertional mutagenesis risk by using non-integrating delivery mechanisms

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses viral vectors as temporary intermediaries that deliver reprogramming factors without permanently integrating into the host genome. The viral DNA remains episomal and is gradually lost during cell division, allowing efficient initial delivery while avoiding permanent genomic integration and associated mutagenesis risks

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If multiple reprogramming factors are delivered simultaneously, then reprogramming completeness is improved, but vector complexity increases

Engineering Contradiction:

Improvereprogramming completenessVSAvoidvector complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines multiple reprogramming factor genes into single viral vector constructs using internal ribosome entry sites (IRES) or 2A self-cleaving peptides to enable co-expression from unified transcriptional units. This merging approach ensures all factors are delivered together to achieve complete reprogramming while simplifying the overall vector design compared to using multiple separate vectors

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The MV vector system significantly increases the efficiency and safety of nuclear reprogramming, producing pluripotent stem cells suitable for regenerative medicine applications, while reducing the risk of tumorigenicity and genomic instability.

Implementation Method 1

the introduction of a target sequence of a microRNA (miRNA; e.g., miR375) into the MV vector can effectively increase the efficiency of reprogramming

Methodology Applied

Scientific EffectMicroRNA binding:

Data Source

PatentUS12529073B2Viral vectors for nuclear reprogramming

Publication Date: 2026.01.20 MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

AI summary

This document provides materials and methods involved in making and using induced pluripotent stem cells (iPSCs). For example, measles virus vectors for reprogramming somatic cells into iPSCs, methods for obtaining iPSCs, and methods for using iPSCs are provided.